OBJECTIVETo observe effects of acupuncture on BMI, WHR and serum levels of leptin and neuropeptide Y in simple obesity Uigur patients to research the mechanism of acupuncture in slimming.

METHODSThirty simple obesity Uigur patients were treated with body acupuncture combined with electroacupuncture. Two courses later, their therapeutic effects were observed. And the above indexes were determined before and after treatment.

RESULTSThe clinical total effective rate was 80.00%, and BMI, WHR, and the serum leptin level decreased (P < 0. 001).

CONCLUSIONUigur patients of simple obesity possibly exist resistance of leptin and acupuncture can decrease the peripheral leptin content.

Acupuncture Therapy ; Electroacupuncture ; Humans ; Leptin ; blood ; Neuropeptide Y ; Obesity ; therapy

OBJECTIVETo compare the difference in effectiveness between the catgut implantation and Fenofibrate for obesity hypertriglyceridemia.

METHODSSeventy-four patients were randomized divided into a catgut implantation group (36 cases) and a medicine group (38 cases). The catgut implantation treatment was applied at the acupoint of Zusanli (ST 36), Fenglong (ST 40), Zhongwan (CV 12), Liangmen (ST 21), Tianshu (ST 25), Quchi (LI 11), Fujie (SP 14), Shangjuxu (ST 37) in catgut implantation group. The treatment of Fenofibrate was used in medicine group. Both treatments last for eight weeks. The level of triglyceride (TG) and the weight were examined in both groups before and after receiving the treatments.

RESULTSThe change value of TG was(1.12 +/- 0.65) mmol/L in catgut implantation group, (1.18 +/- 0.62) mmol/L in medicine group,there was no significant difference between two groups. The weight was (73.1 +/- 6.6) kg in catgut implantation group which was significantly lower than (76.2 +/- 8.6) kg in medicine group (P < 0.01) after treatment.

CONCLUSIONThe effectiveness is comparable in improving the level of hypertriglyceridemia between two groups. The catgut implantation treatment has apparent effect in weight loss; and it is a sound treatment for obesity hypertriglyceridemia.

Acupuncture Points ; Acupuncture Therapy ; Adult ; Catgut ; Female ; Humans ; Hypertriglyceridemia ; blood ; physiopathology ; therapy ; Male ; Middle Aged ; Obesity ; blood ; physiopathology ; therapy ; Treatment Outcome ; Triglycerides ; blood ; Weight Loss ; Young Adult

OBJECTIVETo detect the JAK2, CALR and MPL gene mutations in patients with BCR/ABL1 negative chronic myeloproliferative diseases（BCR/ABL1-CMPD）and to evaluate their diagnostic value.

METHODSTwo hundred and eight cases of BCR/ABL1-CMPD comprising of 146 cases of essential thrombocythemia（ET）, 37 cases of polycythemia vera（PV）and 25 cases of primary myelofibrosis（PMF）from March 2012 to December 2015 were enrolled in the BCR/ABL1-CMPD, while 124 cases of secondary thrombocythemia and 73 cases of secondary polycythemia were enrolled in the control group. The genomic DNA and total RNA Were isolated from bone marrow or peripheral blood, then the exons 12 to 20 of JAK2 gene, exon 10 of MPL gene and exons 3 to 9 of CALR gene were analyzed by using DNA sequencing.

RESULTSamong 146 ET patients, the JAK2, CALR or MPL mutations were found in: 138 cases（94.5%）including 86 cases with JAK2V617F mutation（58.9%）and 2 cases（1.4%）with exon 12 of JAK2 mutations. CALR mutations were detected in 41 cases（28.1%）, among them type 1（c.1092_1143del）in 22 cases, type 2（c.1154_1155insTTGTC）in 11 cases, and type 5（c. 1091_1142del）, type 8（c.1104_1137del）, type 41(c.1107_1137del）, type 42(c.1125_1125del）in one case respectively. In addition, 4 cases were detected withother mutations of the CALR gene（c.1107_1115del, c.1111_1144 del, c.1101 A>C, c.1112_1117del）. Moreover, 9 cases harbored MPL mutations（6.2%）. Secondly, 31 patients were detected with JAK2V617F mutation（83.8%）in 37 cases of PV, and JAK2 exon 12 mutations were found in 2 cases（5.4%）. Besides, CALR mutations were detected in 2 cases（5.4%）, including 1 case of type I, the other of novel mutation of CALR. Thirdly, 19 in 25 cases of PMF were detected with JAK2V617F mutation（76%）, 2 cases with CALR mutations（8%）. 4 patients（16%）, JAK2, CALR or MPL mutations were not detected, but among them 3 cases were found harboring other genetic abnormalities. Fourthly, no mutations of JAK2, MPL and CALR genes were detected in 124 patients with secondary thrombocytosis and 73 cases with secondary polycythemia.

CONCLUSIONCombined detection of JAK2, CALR and MPL gene mutations can cover the vast majority of patients with BCR/ABL1-negative myeloproliferative neoplasms. For higher frequencies of the mutations of CALR in ET patients, CALR mutation can be used as a new diagnostic marker in ET patients with JAK2 and MPL wild type.

Calreticulin ; Humans ; Janus Kinase 2 ; Mutation ; Myeloproliferative Disorders ; Polycythemia Vera ; Receptors, Thrombopoietin ; Thrombocythemia, Essential

OBJECTIVES: To explore the optimal maintenance dose of caffeine citrate for preterm infants requiring assisted ventilation and caffeine citrate treatment. METHODS: A retrospective analysis was performed on the medical data of 566 preterm infants (gestational age ≤34 weeks) who were treated and required assisted ventilation and caffeine citrate treatment in the neonatal intensive care unit of 30 tertiary hospitals in Jiangsu Province of China between January 1 and December 31, 2019. The 405 preterm infants receiving high-dose (10 mg/kg per day) caffeine citrate after a loading dose of 20 mg/kg within 24 hours after birth were enrolled as the high-dose group. The 161 preterm infants receiving low-dose (5 mg/kg per day) caffeine citrate were enrolled as the low-dose group. RESULTS: Compared with the low-dose group, the high-dose group had significant reductions in the need for high-concentration oxygen during assisted ventilation (P=0.044), the duration of oxygen inhalation after weaning from noninvasive ventilation (P<0.01), total oxygen inhalation time during hospitalization (P<0.01), the proportion of preterm infants requiring noninvasive ventilation again (P<0.01), the rate of use of pulmonary surfactant and budesonide (P<0.05), and the incidence rates of apnea and bronchopulmonary dysplasia (P<0.01), but the high-dose group had a significantly increased incidence rate of feeding intolerance (P=0.032). There were no significant differences between the two groups in the body weight change, the incidence rates of retinopathy of prematurity, intraventricular hemorrhage or necrotizing enterocolitis, the mortality rate, and the duration of caffeine use (P>0.05). CONCLUSIONS This pilot multicenter study shows that the high maintenance dose (10 mg/kg per day) is generally beneficial to preterm infants in China and does not increase the incidence rate of common adverse reactions. For the risk of feeding intolerance, further research is needed to eliminate the interference of confounding factors as far as possible.
Caffeine/therapeutic use* ; Citrates ; Humans ; Infant ; Infant, Newborn ; Infant, Premature ; Respiration, Artificial ; Retrospective Studies

OBJECTIVETo investigate the role of cytogenetic analysis in the detection of bone marrow (BM) involvement in patients with non-Hodgkin's lymphoma (NHL).

METHODSThe bone marrow samples of 74 patients with NHL were detection by using morphology, cytogenetic test, flow cytometry and molecular biological assay. The detected results of morphology, cytogenetic test, flow cytometry and molecular biological assay alone and thier combined detection were compared, the detective rate and consistencies of the 4 methods were analyzed.

RESULTSThe detection rates of BM involvement by using morphology, cytogenetic, flow cytometry, and molecular biological assays were 21.6%, 17.6%, 23.0% and 33.8% respectively. The detective rate was enhanced to 44.6% by combining the 4 methods. Cytogenetic test showed the result consistent with the other methods.

CONCLUSIONAlthough cytogenetic test shows a lower detective rate than the other methods, but in some patients the cytogenetic test can detect the abnormality of bone marrow which can not be detected by other methods alone, the combination test of 4 detection methods can enhance the detectable rate of BM involvement.

Bone Marrow ; pathology ; Bone Marrow Examination ; Cytogenetic Analysis ; Flow Cytometry ; Humans ; Lymphoma, Non-Hodgkin ; diagnosis ; genetics